A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor–dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2

Autor: Madeline Flores, Garth S. Herbert, Jonathan Martin, Diane F. Hale, Xianzhong Yu, George E. Peoples, Mark O. Hardin, Julia M. Greene, Doreen O. Jackson, Timothy J. Vreeland, Erika J Schneble, Thomas E. Wagner
Rok vydání: 2016
Předmět:
Zdroj: Cancer Immunology, Immunotherapy. 65:383-392
ISSN: 1432-0851
0340-7004
Popis: Stage IV melanoma has high mortality, largely unaffected by traditional therapies. Immunotherapy including cytokine therapies and checkpoint inhibitors improves outcomes, but has significant toxicities. In this phase I/IIa trial, we investigated safety and efficacy of a dendritoma vaccine, an active, specific immunotherapy, in stage IV melanoma patients. Autologous tumor lysate and dendritic cells were fused creating dendritoma vaccines for each patient. Phase I patients were vaccinated every 3 months with IL-2 given for 5 days after initial inoculation. Phase IIa patients were vaccinated every 6 weeks with IL-2 given on days 1, 3 and 5 after initial inoculation. Toxicity and clinical outcomes were assessed. Twenty-five patients were enrolled and inoculated. All dendritoma and IL-2 toxicities were
Databáze: OpenAIRE